{"status": "ok", "totalResults": 3, "articles": [{"source": {"id": "financial-times", "name": "Financial Times"}, "author": "Donato Paolo Mancini", "title": "EU delays approval of Novavax's revised Covid jab - Financial Times", "description": "US biotech has been struggling to overcome fall in demand for coronavirus jabs", "url": "https://www.ft.com/content/2e10b2ab-7d0c-48a3-b49b-8de8dc302c6d", "urlToImage": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fd1e00ek4ebabms.cloudfront.net%252Fproduction%252Fc9b25c15-a093-40f3-9f88-bf24f741d9bf.jpg%3Fsource%3Dnext-article%26fit%3Dscale-down%26quality%3Dhighest%26width%3D700%26dpr%3D1?source=next-opengraph&fit=scale-down&width=900", "publishedAt": "2023-10-15T04:00:36Z", "content": "EU regulators have delayed a decision to approve Novavaxs variant-tailored Covid-19 vaccine, in a setback for the US-listed biotech which is battling a slump in demand for coronavirus jabs.\r\nThe Euro\u2026 [+2445 chars]"}, {"source": {"id": "financial-times", "name": "Financial Times"}, "author": "Colby Smith, Sam Fleming", "title": "Fears of wider Middle East conflict cast shadow over global economy - Financial Times", "description": "Risk of rising oil prices and hit to confidence threaten to undermine this year\u2019s gains", "url": "https://www.ft.com/content/3c358b32-33ff-4118-841c-689c27a4dd89", "urlToImage": null, "publishedAt": "2023-10-15T04:00:07Z", "content": "What is included in my trial?\r\nDuring your trial you will have complete digital access to FT.com with everything in both of our Standard Digital and Premium Digital packages.\r\nStandard Digital includ\u2026 [+1494 chars]"}, {"source": {"id": "financial-times", "name": "Financial Times"}, "author": "Hannah Kuchler", "title": "Novo Nordisk raises profit guidance as weight-loss drug sales boom - Financial Times", "description": "Danish drugmaker behind Wegovy and Ozempic has become Europe\u2019s biggest company", "url": "https://www.ft.com/content/e7200651-8659-4c3b-8913-a9e3486f0a5b", "urlToImage": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fd1e00ek4ebabms.cloudfront.net%252Fproduction%252F314f62d1-0043-4a8e-82c7-11a6c1a33185.jpg%3Fsource%3Dnext-article%26fit%3Dscale-down%26quality%3Dhighest%26width%3D700%26dpr%3D1?source=next-opengraph&fit=scale-down&width=900", "publishedAt": "2023-10-13T14:01:59Z", "content": "Soaring sales of weight loss and diabetes drugs Wegovy and Ozempic have pushed Europes largest company Novo Nordisk to raise its full-year revenue and profits guidance.\r\nThe Danish drugmaker now expe\u2026 [+2198 chars]"}]}